Inhibition of Pol I transcription treats murine and human AML by targeting the leukemia-initiating cell population

Nadine Hein; Donald P. Cameron; Katherine M. Hannan; Nhu-Y.N. Nguyen; Chun Yew Fong; Jirawas Sornkom; Meaghan Wall; Megan Pavy; Carleen Cullinane; Jeannine Diesch; Jennifer R. Devlin; Amee J. George; Elaine Sanij; Jaclyn Quin; Gretchen Poortinga; Inge Verbrugge; Adele Baker; Denis Drygin; Simon J. Harrison; James D. Rozario; Jason A. Powell; Stuart M. Pitson; Johannes Zuber; Ricky W. Johnstone; Mark A. Dawson; Mark A. Guthridge; Andrew H. Wei; Grant A. McArthur; Richard B. Pearson; Ross D. Hannan

doi:10.1182/blood-2016-05-718171

Related publications

Article2016

The Dual Inhibition of RNA Pol I Transcription and PIM Kinase as a New Therapeutic Approach to Treat Advanced Prostate Cancer

Richard J. Rebello, Eric Kusnadi, Donald P. Cameron, Helen Pearson, Analia Lesmana, Jennifer R. Devlin, Denis Drygin, Ashlee K. Clark, Laura H. Porter, John Pedersen, Shahneen Sandhu, Gail P. Risbridger, Richard B. Pearson, Ross D. Hannan, Luc Furic

Article2016

The dual inhibition of RNA Pol I transcription and PIM kinase as a new therapeutic approach to treat advanced prostate cancer

Richard J. Rebello, Eric Kusnadi, Donald P. Cameron, Helen Pearson, Analia Lesmana, Jennifer R. Devlin, Denis Drygin, Abbe R. Clark, Lisa A. Porter, J. Pedersen, Shahneen Sandhu, Gail P. Risbridger, Richard B. Pearson, Ross D. Hannan, Luc Furic

Article2016

Abstract 5181: Dual inhibition of RNA Pol I transcription and PIM kinase as a new therapy to treat prostate cancer

Richard J. Rebello, Eric Kusnadi, Donald P. Cameron, Analia Lesmana, Denis Drygin, Ashlee K. Clark, Laura H. Porter, Shahneen Sandhu, Gail P. Risbridger, Richard B. Pearson, Ross D. Hannan, Luc Furic

Article2009

Inhibition of the proteasome influences murine and human dendritic cell development in vitro and in vivo

Elisabeth Zinser, Susanne Rößner, Leonie Littmann, Daniel Lüftenegger, Ulrich Sigmar Schubert, Alexander Steinkasserer

Preprint2023

Data from The Dual Inhibition of RNA Pol I Transcription and PIM Kinase as a New Therapeutic Approach to Treat Advanced Prostate Cancer

Richard J. Rebello, Eric Kusnadi, Donald P. Cameron, Helen Pearson, Analia Lesmana, Jennifer R. Devlin, Denis Drygin, Ashlee K. Clark, Laura S. Porter, J.K. Pedersen, Shahneen Sandhu, Gail P. Risbridger, Richard B. Pearson, Ross D. Hannan, Luc Furic

Inhibition of Pol I transcription treats murine and human AML by targeting the leukemia-initiating cell population

Discussion(0)

Related publications

The Dual Inhibition of RNA Pol I Transcription and PIM Kinase as a New Therapeutic Approach to Treat Advanced Prostate Cancer

The dual inhibition of RNA Pol I transcription and PIM kinase as a new therapeutic approach to treat advanced prostate cancer

Abstract 5181: Dual inhibition of RNA Pol I transcription and PIM kinase as a new therapy to treat prostate cancer

Inhibition of the proteasome influences murine and human dendritic cell development in vitro and in vivo

Data from The Dual Inhibition of RNA Pol I Transcription and PIM Kinase as a New Therapeutic Approach to Treat Advanced Prostate Cancer